Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.56 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20147357 | 0.87 | KDM4E (0.48) | SMN1; SMN2KDM4EHSD17B10TSHRMEN1 | |
| SCHEMBL17033039 | 0.79 | CHRM5 (0.56) | KDM4EMEN1KMT2AALDH1A1 | |
| SCHEMBL17031741 | 0.79 | SMN1; SMN2 (0.51) | SMN1; SMN2KDM4EHSD17B10TSHRLMNA | |
| SCHEMBL31461525 | 0.78 | SMN1; SMN2 (0.50) | SMN1; SMN2KDM4EHSD17B10TSHRMEN1 | |
| SCHEMBL30252383 | 0.77 | SMN1; SMN2 (0.53) | SMN1; SMN2KDM4EHSD17B10TSHRKMT2A | |
| SCHEMBL20070114 | 0.76 | SMN1; SMN2 (0.49) | SMN1; SMN2KDM4ELMNAALDH1A1USP2 | |
| SCHEMBL427989 | 0.76 | SMN1; SMN2 (0.66) | SMN1; SMN2KDM4EHSD17B10TSHRMEN1 | |
| SCHEMBL31053557 | 0.74 | SMN1; SMN2 (0.68) | SMN1; SMN2KDM4EHSD17B10TSHRLMNA | |
| SCHEMBL8429732 | 0.73 | SMN1; SMN2 (0.72) | SMN1; SMN2KDM4EHSD17B10TSHRMEN1 | |
| SCHEMBL20147364 | 0.72 | MEN1 (0.49) | SMN1; SMN2HSD17B10TSHRMEN1CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9758537-B2 | Compounds for treatment of complement mediated disorders | ACHILLION PHARMACEUTICALS (US) | 2017-09-12 | — | — | US | disclosed |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2016-12-15 | — | — | US | disclosed |
| WO-2015130854-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-09-03 | — | — | WO | disclosed |
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | ACHILLION PHARMACEUTICALS, INC. (US) | 2015-08-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150239838-A1 | Compounds for Treatment of Complement Mediated Disorders | CFD, TFPI, CFH | SMN1; SMN2 1571/4885KDM4E 4628/4885HSD17B10 4303/4885 |
| US-20160361329-A1 | COMPOUNDS FOR TREATMENT OF COMPLEMENT MEDIATED DISORDERS | CFD, CFH, TFPI | SMN1; SMN2 2008/4885KDM4E 4497/4885HSD17B10 2221/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.